Baxter International Inc
NYSE:BAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Baxter International Inc
Net Issuance of Debt
Baxter International Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Baxter International Inc
NYSE:BAX
|
Net Issuance of Debt
-$3.8B
|
CAGR 3-Years
-62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Issuance of Debt
-$491m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Issuance of Debt
$1.6B
|
CAGR 3-Years
50%
|
CAGR 5-Years
10%
|
CAGR 10-Years
42%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Issuance of Debt
-$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-14%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Baxter International Inc
Glance View
Baxter International Inc. finds its roots in the early 1930s, a time when the healthcare landscape was vastly different. Founded by Donald Baxter, a medical doctor seeking to improve the quality and safety of intravenous therapy, the company initially focused on researching and developing safe ways to provide patients with sterile intravenous solutions. As the years unfolded, Baxter transformed itself from a small operation into a globally recognized healthcare giant. Today, it operates in the realm of lifesaving medical products and services, specializing in the development of essential pharmaceuticals, clinical nutrition for hospitals, advanced kidney care solutions, and critical care technology that healthcare providers depend on daily. Central to Baxter's business model is its commitment to innovation and improving patient outcomes, which drives its success and profitability. By leveraging its expertise in areas like renal and hospital products, Baxter is able to cultivate a diversified portfolio. This diversification not only helps the company mitigate risks but also strengthens its market position. Revenue streams are generated through the manufacture and sale of medical devices and pharmaceuticals, catering mostly to hospitals, clinics, and renal care centers worldwide. Baxter consistently reinvests in its research and development, aiming to pioneer novel therapies and products that address the evolving needs of the healthcare sector, ensuring that it remains a key player in the ongoing story of medical progress.
See Also
What is Baxter International Inc's Net Issuance of Debt?
Net Issuance of Debt
-3.8B
USD
Based on the financial report for Dec 31, 2025, Baxter International Inc's Net Issuance of Debt amounts to -3.8B USD.
What is Baxter International Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-62%
Over the last year, the Net Issuance of Debt growth was -614%. The average annual Net Issuance of Debt growth rates for Baxter International Inc have been -62% over the past three years .